Abstract: Provided in the present invention are a magnetic nanosphere coated with modified cardiolipin, and manufacturing method thereof. The magnetic nanosphere coated with modified cardiolipin comprises a modified cardiolipin, a biotin derivative, and a streptavidin magnetic bead. The modified cardiolipin is coupled to the biotin derivative via an —NH—CO structure. The streptavidin magnetic bead is a magnetic nanosphere coupled to streptavidin, and the biotin derivative is coupled to the streptavidin.

Abstract: The invention provides a method that gives direct information about the intervention of a potential drug on the secondary structure distribution of a targetbiomolecule, i.e., for a disease with misfolded protein, such as neurodegenerative diseases in a complex body fluid. The secondary structural change is monitored by vibrational spectroscopy. The method can be applied for prescreening of drug candidates for targeting of specific biomolecules. The effect of the drug on the secondary structure distribution is monitored label-free in real time and provides thereby direct information about the efficacy of the potential drug.

Abstract: Disclosed herein are embodiments of nanohoop compounds and conjugates thereof that can be used myriad biological applications. The nanohoop compounds described herein can exhibit beneficial properties that are useful in biotechnology, such as a fluorescent tag, probe, or label.

Abstract: Provided are an additive and a surface treatment agent capable of suppressing agglutination of latex particles contained in a reagent for a latex agglutination reaction during storage of the reagent although a synthetic polymer is contained as an active component. An additive is to be added to latex particles used in a reagent for a latex agglutination reaction. The latex particles have not been subjected to blocking treatment. The additive includes a polymer containing more than 60% by mass and 99% by mass or less of hydrophilic repeating units (A) relative to all repeating units and 1% by mass or more and less than 40% by mass of hydrophobic repeating units (B) relative to all repeating units, and having a weight average molecular weight of 3,000 or more.

Abstract: The invention relates to methods for the diagnosis of ischemia or ischemic tissue damage, methods for predicting the progression of ischemia in a patient having suffered an ischemic event, for determining the prognosis of a patient having suffered an ischemic event and for determining the risk that a patient suffering from stable coronary disease suffers a recurrent ischemic event based on the detection of the levels of glycosylated Apo J. The invention relates as well to a method for the determination of glycosylated Apo J in a sample.

Abstract: The present invention relates to a method for measuring the cholesterol uptake capacity of lipoproteins. The present invention also relates to a reagent kit for measuring the cholesterol uptake capacity of lipoproteins. The present invention further relates to a tagged cholesterol which can be used in the method and the reagent kit.

Abstract: The present disclosure generally relates to nanoparticles adsorbed with gliadin molecules. In addition, the present disclosure relates to methods of preparing the nanoparticles adsorbed with gliadin molecules and methods of using said nanoparticles including detecting anti-gliadin 5 antibodies in a sample, diagnosing gluten-related disorders, and other applications.

Abstract: A compound is provided which is effectively adsorbed to a substrate surface, such as an immune reaction vessel, has extremely high protein adsorption inhibitory effect that inhibits non-specific adsorption of protein or the like, and has excellent washability to retain the inhibitory effect before and after washing operation of the substrate. Also provided are a protein adsorption inhibitor using the compound, a phosphorylcholine-modified substrate, and a method for inhibiting protein adsorption. The compound is a phosphorylcholine group-containing polyethylene glycol derivative represented by formula (1). The method for inhibiting protein adsorption of the present invention includes the step of forming an adsorbed layer of the derivative on a substrate surface.

Abstract: An object of the present invention is to provide a blood analysis method and a blood test kit, which are capable of performing measurement of a plurality of target components to be analyzed with high accuracies in a case where hemolysis occurs in a case of measuring an amount of target components to be analyzed in a small volume of a blood sample.

Abstract: It is an object of the present invention to provide a tissue staining method that makes it possible to observe both information on the morphology of a tissue and information on a biological substance such as an antigen molecule to be detected on a single section and in a single view field. The present invention provides a tissue staining method, including carrying out (A) a HE (hematoxylin-eosin) staining, and (B) a histochemical staining, serially on a single tissue section, wherein the histochemical staining is defined as a histochemical technique for detecting a biological substance to be detected in a tissue in a visible manner by use of a binding reaction between the biological substance to be detected and a probe biological substance capable of binding specifically to the biological substance to be detected.

Abstract: Methods for producing high concentration protein formulations having high stability are provided. Assays for selecting proteins and formulation conditions that have high self-repulsive attributes are used as an early step in the manufacturing process. Specifically, a protein concentration-dependent self-interaction nanoparticle spectroscopy method is employed as a protein colloidal interaction assay.

Abstract: The present invention concerns an in vitro method for measurement of 25-hydroxyvitamin D, wherein the potentially interfering compound 24,25-dihydroxyvitamin D3 is blocked by a binding agent specifically binding to 24,25-dihydroxyvitamin D3 and not binding to 25-hydroxyvitamin D.

Abstract: Methods, systems, and software are provided for using organoid cultures, e.g., patient-derived tumor organoid cultures, to improve treatment predictions and outcomes.

Abstract: Lyophilized chromophoric polymer dot compositions are provided. Also disclosed are methods of making and using the lyophilized compositions, methods of dispersing the lyophilized compositions in aqueous solutions and kits supplying the compositions.

Abstract: Disclosed is a method for measurement of an analyte in a microparticle-based analyte-specific binding assay, wherein the microparticles are coated with the first partner of a binding pair, the method involving mixing the coated microparticles, an analyte-specific binding agent conjugated to the second partner of the binding pair, and a sample suspected of containing or containing the analyte, wherein the second partner of the binding pair is bound to the analyte-specific binding agent via a linker having from 12 to 30 ethylene glycol units (PEG 12 to 30), thereby binding the analyte via the conjugated analyte-specific binding agent to the coated microparticles, separating the microparticles having the analyte bound via the binding pair and the analyte-specific binding agent from the mixture and measuring the analyte bound to the microparticles.

Abstract: Disclosed is an analyte detection method, including detecting an analyte in such a state that a complex composed of the analyte in a sample of interest, a particle capable of bonding to the analyte and a trapping substance capable of bonding to the analyte is formed on a substrate, wherein the analyte is detected on the basis of an index associated with a behavior of the particle.

Abstract: The present invention may provide phosphor-integrated nanoparticles whose precipitation and/or aggregation, particularly aggregation can be inhibited upon carrying out immunostaining therewith and which can thus be used for staining even after long-term storage without requiring a complicated operation, the phosphor-integrated nanoparticles preferrably maintaining excellent performance, such as staining properties, even after long-term storage. The phosphor-integrated nanoparticles of the present invention have an average sphericity (f) of 0.80 to 0.95 and preferably have an average circumference ratio (R) of 0.50 to 0.95.

Abstract: A method for exchange imaging of at least two targets in a sample includes (a) incubating a sample with at least two or more target-recognizing antibodies, each bound to a corresponding monovalent tight antibody binder-docketing moiety (MTAB-DM) reagent capable of binding monovalently to the target-recognizing antibodies, (b) applying at least two imager moieties corresponding to the MTAB-DM, either in series, in batches, or in parallel, and (d) imaging the at least two imager moieties either in series, in batches, or in parallel.

Abstract: The present invention relates to tri-functional crosslinking reagents carrying (i) a ligand-reactive group for conjugation to a ligand of interest having at least one binding site on a target glycoprotein receptor, (ii) a hydrazone group for the capturing of oxidized receptor-glycoproteins and (iii) an affinity group selected from azides and alkynes for the detection, isolation and purification of captured glycoproteins; as well as their manufacturing. The invention further provides for improved methods of detecting, identifying and characterizing interactions between ligands and their corresponding target glycoproteins on living cells and in biological fluids. The invention further provides for new uses of catalysts in such methods.

Abstract: A biological substance detection method for detecting a biological substance specifically in a pathological specimen, includes a step of immunologically staining the pathological specimen using a fluorescent label, a step of staining the pathological specimen with a staining reagent for morphology observation purposes (eosin) to observe the morphology of the pathological specimen, a step of irradiating the stained pathological specimen with excited light to cause the emission of a fluorescent and detecting the biological substance in the pathological specimen. In the step of immunologically staining the pathological specimen, a special fluorescent particle for which the excitation wavelength appears in a region that is different from the excitation wavelength region of eosin is used as the fluorescent label.